GlassScriptPhysician profile
Damon K Travis
NPI 1578583852
$19,306.64
in general payments reported to CMS, 2019-2025
74 companies · $2,808 in 2025
The $2,808 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $1,772 · 2021: $2,712 · 2022: $3,672 · 2023: $3,118 · 2024: $2,723 · 2025: $2,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,649 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,648.77 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,480.32 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,859.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,579.44 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $1,367.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,190.41 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $775.22 | 2019-2022 | |
| Lilly USA, LLC | $578.02 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Otsuka America Pharmaceutical, INC. | $538.24 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $536.24 | 2021-2025 | Caplyta |
| Glaxosmithkline, LLC. | $517.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $453.13 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $447.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $443.92 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $427.59 | 2019-2023 | |
| Qol Medical, LLC | $409.91 | 2023-2025 | Sucraid, Sucraid |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.